

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Protocol for a feasibility randomised trial of low intensity interventions for antenatal depression: ADAGIO trial comparing Interpersonal Counselling with Cognitive Behavioural Therapy.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032649
Article Type:	Protocol
Date Submitted by the Author:	28-Jun-2019
Complete List of Authors:	Ingram, Jenny; University of Bristol, Bristol Medical School, Centre for Academic Child Health Johnson, Debbie; University of Bristol, Bristol Medical School, Centre for Academic Child Health Johnson, Sarah; University Hospitals Bristol NHS Foundation Trust O'Mahen, Heather; University of Exeter Kessler, David; University of Bristol, Taylor, Hazel; University Hospitals Bristol NHS Foundation Trust Law, Roslyn; Anna Freud Centre Round, Jeff; Institute of Health Economics Ford, Jenny Hopley, Rebecca; University of Exeter Glynn, Joel; University of Bristol Culpin, I; University of Bristol, Bristol Medical School Evans, Jonathan; University Of Bristol, Bristol Medical School
Keywords:	MENTAL HEALTH, Depression & mood disorders < PSYCHIATRY, Pregnancy

SCHOLARONE™  
Manuscripts

1  
2  
3 **Protocol for a feasibility randomised trial of low intensity interventions for antenatal**  
4 **depression: ADAGIO trial comparing Interpersonal Counselling with Cognitive**  
5 **Behavioural Therapy.**  
6

7 Jenny Ingram<sup>1</sup>,

8  
9 Debbie Johnson<sup>1</sup>,

10 Sarah Johnson<sup>2</sup>,

11  
12 Heather O'Mahen<sup>3</sup>,

13  
14 David Kessler<sup>4</sup>,

15  
16 Hazel Taylor<sup>5</sup>,

17 Roslyn Law<sup>6</sup>,

18  
19 Jeff Round<sup>7</sup>,

20  
21 Jenny Ford<sup>2</sup>,

22  
23 Becky Hopley<sup>3</sup>,

24  
25 Joel Glynn<sup>8</sup>,

26  
27 Iryna Culpin<sup>4</sup>,

28  
29 Jonathan Evans<sup>4</sup>  
30

31 <sup>1</sup> Centre for Academic Child Health, Bristol Medical School, University of Bristol, UK.

32 <sup>2</sup> University Hospitals NHS Foundation Trust, Bristol, UK

33 <sup>3</sup> Department of Psychology, University of Exeter, UK

34 <sup>4</sup> Centre for Academic Mental Health, Bristol Medical School, University of Bristol, UK.

35  
36  
37 <sup>5</sup> Research Design Service- South West, University Hospitals NHS Foundation Trust, Bristol,  
38 UK

39  
40 <sup>6</sup> Anna Freud National Centre for Children and Families, London, UK

41  
42 <sup>7</sup> Institute of Health Economics, Alberta, Canada; and Health Economics Bristol, University  
43 of Bristol, UK

44  
45 <sup>8</sup> Health Economics Bristol, Bristol Medical School, University of Bristol, UK  
46  
47  
48  
49  
50

51 Corresponding author: Dr Jenny Ingram, Centre for Academic Child Health, University of  
52 Bristol, Bristol Medical School, 1-5 Whiteladies Road, Bristol BS8 1NU. 0117 428 3095;

53  
54  
55 Email: [jenny.ingram@bristol.ac.uk](mailto:jenny.ingram@bristol.ac.uk).  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction.** One in eight women suffer from depression during pregnancy. Currently low intensity brief treatment based on cognitive behavioural therapy (CBT) is the only talking treatment widely available in the NHS for mild and moderate depression. CBT involves identifying and changing unhelpful negative thoughts and behaviours to improve mood. Mothers in our patient advisory groups requested greater treatment choice. Interpersonal counselling (IPC) is a low intensity version of interpersonal therapy. It may have important advantages during pregnancy over CBT because it targets relationship problems, changes in role and previous losses (e.g. miscarriage). We aim to compare CBT and IPC for pregnant women with depression in a feasibility study.

**Methods and analysis:** A two-arm non-blinded randomised feasibility study of 60 women will be conducted in two UK localities. Women with depression will be identified through midwife clinics and ultrasound scanning appointments and randomised to receive six sessions of IPC or CBT. In every other way these women will receive usual care. Women thought to have severe depression will be referred for more intensive treatment. After 12 weeks we will measure women's mood, well-being, relationship satisfaction and use of health care. Women, their partners and staff providing treatments will be interviewed to understand whether IPC is an acceptable approach and whether changes should be introduced before applying to run a larger trial.

Several groups of patients with depression during pregnancy have contributed to our study design. A patient advisory group will meet and advise us during the study.

**Ethics and dissemination:** Study results will inform the design of a larger multicentre RCT. Our findings will be shared through public engagement events, papers and reports to organisations within the NHS. National Research Ethics Service Committee approved the study protocol.

Trial registration number: ISRCTN 11513120

**Article summary.****Strengths and limitations of the study.**

- Psychological treatment provision during pregnancy is important due to the consequences of depression at this time and uncertainty over the use of antidepressants during pregnancy. IPC is particularly relevant to issues that may arise in pregnancy and therefore the advantages of this approach over standard CBT treatment may be greater than at other times.
- This study uses a two-centre randomised controlled trial design to determine the feasibility of a definitive trial.
- A process evaluation will explore the fidelity of intervention delivery and the experience of women, partners (or a significant other) and therapists.
- A definitive trial would be necessary to evaluate the effectiveness of the intervention.

Key words: Antenatal depression; Cognitive behavioural therapy; interpersonal counselling.

## INTRODUCTION.

Antenatal depression is common, with a reported prevalence of 11%<sup>1</sup> and a point prevalence of up to 44% in certain populations.<sup>2</sup> Antenatal depression is associated with a range of poor outcomes including continuing depression into the postnatal period, reduced breastfeeding rates<sup>3</sup>, infant developmental delay<sup>4</sup>, and social/emotional problems, including depression in the offspring during adolescence.<sup>5</sup> Pregnancy does not appear to be protective against developing depression or relapsing in those with a previous history of depression.<sup>6</sup>

Currently, the Whooley questions are used to identify women who may have antenatal depression.<sup>7</sup> This screening method has high sensitivity (95%) and modest specificity (65%) for antenatal depression.<sup>8</sup> However, anecdotal evidence suggests that women are not always aware that they are referred for further help following a positive Whooley screen.<sup>9</sup>

There is limited evidence for the effectiveness of psychological interventions for antenatal depression<sup>10</sup>, despite a widespread reluctance of mothers to take antidepressants during pregnancy<sup>11</sup> with 75% of women discontinuing antidepressant medication in the first trimester.<sup>12</sup> There is also concern amongst clinicians about prescribing antidepressant medication<sup>13</sup>, largely due to a lack of evidence regarding their safety<sup>14</sup>, indicating that psychological interventions are particularly important at this time.<sup>10,15</sup> One study found that women who discontinue antidepressant medication during pregnancy are five times more likely to experience a relapse in their depression requiring treatment.<sup>6</sup> The current treatment recommendation for mild to moderate depression, including depression that occurs during pregnancy, is a brief, one to one supported self-help approach using the principles of cognitive behavioural therapy (CBT) known as low intensity CBT.

### *Theoretical basis of CBT and limitations for this population.*

The theoretical basis of CBT is that individuals prone to depression hold dysfunctional beliefs and therefore see the world through a negative filter.<sup>16</sup> Adversity, such as pregnancy, triggers these underlying beliefs and prone individuals then behave in a way that is consistent with these negative beliefs thus triggering and reinforcing depression. There is no specific relevance of this model to pregnancy and it relies on the skill of the therapist to adapt CBT to individual circumstances. Although there is a growing evidence base for 'high intensity' CBT delivered by experienced therapists for perinatal depression, 'low intensity' CBT is briefer and delivered by less experienced practitioners who have limited scope to adapt to the perinatal context and be flexible in its use. The use of high intensity CBT is limited within current clinical frameworks due to limitations in funding and therapist

1  
2  
3 availability. CBT has few explicit strategies to manage many of the problems that are  
4 common for women with antenatal depression, including role transitions and problems in  
5 relationships.  
6  
7

8  
9 A recent review highlighted the need for more personalized therapies to treat perinatal  
10 depression, including interpersonal psychotherapy as a plausible treatment option.<sup>17</sup> Women  
11 in our patient advisory group consultations reported that CBT is 'too clinical' and 'inflexible'  
12 with practitioners not appearing to consider the circumstances of pregnancy. This may be  
13 one reason why the uptake of CBT treatment for antenatal depression is low. It has been  
14 reported that 14% of women with antenatal depression receive psychological treatment and  
15 only 5% with antenatal depression achieve remission following treatment.<sup>18</sup> Women who are  
16 pregnant receive lower rates of psychological intervention than those outside the perinatal  
17 period (30% vs 50%) despite an increased need for psychological treatment rather than drug  
18 treatment at this time.  
19  
20  
21  
22  
23  
24  
25

26  
27 *Theoretical basis of Interpersonal Counselling (IPC) and advantages for treating antenatal*  
28 *depression.*  
29

30 IPC is a brief treatment which may be more appropriate for addressing the problems that  
31 depressed women have during pregnancy and postnatally. It is derived from interpersonal  
32 therapy, which holds that interpersonal relationships are a basic human need and  
33 attachment to key individuals provides a secure base from which to manage stressful events  
34 and conditions.<sup>19</sup> Problems in interpersonal relationships can trigger symptoms of  
35 depression, such as low mood or sleeplessness, and these symptoms further compromise  
36 relationships leading to a downward spiral.<sup>20</sup> This is particularly relevant to pregnancy as  
37 conflict in relationships and poor social support are the strongest risk factors for antenatal  
38 depression.<sup>21</sup>  
39  
40  
41  
42  
43  
44  
45

46 IPC offers a more structured version of IPT that promotes understanding of depression  
47 through psychoeducation, problem solving and active involvement of the people in the  
48 person's life to provide support and promote recovery. IPC helps individuals develop useful  
49 strategies to manage interpersonal conflict and can involve the partner if appropriate. It also  
50 focuses on approaches that help manage changes in role, conflict, isolation and loss (i.e.,  
51 miscarriage, still-birth, termination, previous loss of would be grandparents) and the impact  
52 of these on relationships. By directly approaching these issues, IPC addresses what is  
53 theoretically central to depression and what service users report are significant worries and  
54 concerns for them. The approach is simple and focused and could be provided by  
55 practitioners who have limited training or experience.  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 Currently there are limited data on the effectiveness of IPC.<sup>14</sup> It is critical to test its  
6 effectiveness because although almost half (43%, n=201,591 in 2015-16) of all individuals  
7 who receive a talking treatment in the NHS will receive a brief, “low-intensity” treatment,  
8 interpersonal brief treatment approaches are currently not available in the NHS.<sup>22</sup>  
9  
10

11  
12 IPC has been clearly developed and rigorously manualised as an intervention allowing  
13 assessment of fidelity to the model. Although there have been very few studies of the  
14 effectiveness of IPC, and none in the UK, one study of depression in primary care in Italy  
15 found IPC to be more effective than antidepressants (SSRIs) particularly for those with less  
16 severe depression.<sup>23</sup> and a small UK pilot study found that IPC is an effective and  
17 acceptable treatment for young people with primarily depressive symptoms.<sup>24</sup> A small  
18 feasibility study of IPC for antenatal depression in the US amongst low income mothers  
19 indicated high satisfaction with IPC and some improvement in mood.<sup>25</sup>  
20  
21  
22  
23  
24  
25

26  
27 There are therefore good reasons to hypothesise that IPC may be more acceptable at this  
28 time and particularly effective in treating antenatal depression. There is some evidence that  
29 interpersonal therapy (IPT), a high intensity therapy from which IPC is derived, is more  
30 acceptable than 'high intensity' CBT, with sessions more likely to be attended and that  
31 outcomes are better for IPT than 'high intensity' CBT in existing psychological treatment  
32 services.<sup>22</sup> We argue that evaluating this intervention for treating antenatal depression is  
33 particularly important because:  
34  
35  
36  
37

- 38 1) the model is particularly relevant to pregnancy and therefore the advantages of this  
39 approach over standard CBT treatment may be greater than at other times.<sup>26</sup>
- 40 2) psychological treatment provision is a priority at this time because of the potential risks of  
41 antidepressants during pregnancy and the costs of depression during pregnancy.<sup>27</sup>  
42  
43  
44  
45

46 Training low-intensity practitioners in IPC has the potential to offer women an acceptable,  
47 empirically valid option which may prove to be more effective than CBT and provide the NHS  
48 with a treatment option that may be both effective and cost-effective.  
49  
50  
51

## 52 **AIMS and OBJECTIVES.**

53  
54  
55 Our overall aim is to improve psychological treatment for depression during pregnancy in  
56 order to improve outcomes for the mother, infant and the wider family. We aim to test  
57 whether six sessions of IPC are acceptable, effective and cost effective for treating mild to  
58 moderate antenatal depression compared to the most commonly provided existing  
59  
60



1  
2  
3 intervention, low intensity cognitive behavioural therapy (CBT). Both interventions are one to  
4 one therapies comprising up to six sessions.  
5  
6  
7

8 The aim of this first study is to establish the feasibility and acceptability of conducting a full  
9 scale randomised controlled trial to compare the effectiveness of these two low intensity  
10 interventions for antenatal depression. Using a pragmatic study design operating within the  
11 existing care pathway, we will explore whether a full-scale trial using such a design is  
12 feasible. Study objectives are shown in Box 1.  
13  
14  
15  
16

### 17 **Box 1: Detailed study objectives**

18 To determine whether a full trial is feasible by assessing:  
19

- 20  
21  
22 1) Whether staff who currently deliver low intensity interventions within routine  
23 psychological treatment services, known nationally as Improving Access to Psychological  
24 Treatment (IAPT) services, can reliably deliver this newly adapted therapy after brief,  
25 additional training.  
26  
27 2) Whether it is possible to recruit women from community midwife booking clinics and  
28 through screening at the ultrasound scanning clinics.  
29  
30 3) Whether it is feasible and acceptable to randomise women following assessment.  
31  
32 4) How acceptable IPC is to women, partners and those delivering the intervention relative  
33 to low intensity CBT, assessed through qualitative interviews.  
34  
35 5) Whether it is possible to collect sufficient outcome data, including those required to  
36 perform an economic evaluation.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 44 **METHODS AND ANALYSIS.**

### 46 **Study design.**

48 This feasibility study over 21 months will be carried out in two centres (site A and site B), in  
49 preparation for a pragmatic fully powered RCT. Women with mild to moderate depression  
50 during pregnancy considered suitable for a low intensity intervention will be randomised 1:1  
51 either to the usual low intensity treatment (CBT) or to a novel treatment called interpersonal  
52 counselling (IPC).  
53  
54  
55  
56  
57  
58  
59  
60

### Study population, setting and recruitment plan

Women who are aged 18 years or over are eligible for inclusion between 10 and 24 weeks of pregnancy, with an Edinburgh Depression Scale (EPDS) score 10 or above and mild or moderate depression according to Clinical Interview Schedule Revised (CIS-R)<sup>28</sup>, which gives an ICD-10 diagnosis, whether or not they are taking an antidepressant. Both primiparous and multiparous women will be eligible. Recruitment will continue for 9 months.

We will exclude women with psychotic illness, organic brain disorder, bipolar disorder, personality disorder, alcohol or substance dependency, which will be identified through self-report. Also excluded will be those judged to be at high suicide risk in assessor's judgement or from response to items on suicide in CIS-R or EPDS, those with severe depression according to CIS-R criteria, and those who have had CBT or IPT within the last 6 months. If women miscarry or have a termination during the trial, they will be offered the opportunity to continue with the treatment but will not be included in the rest of the study.

We will compare recruitment through two routes which have been used successfully in two previous trials of antenatal depression and antenatal anxiety:<sup>29, 30</sup>

Method 1: Women will be identified at community midwife booking clinics (around 8-10 weeks' gestation) through the routine screening undertaken for depression using the Whooley questions.<sup>8</sup> Those who answer 'yes' to either question and are considered by the midwife to be appropriate for further assessment for talking therapy, will be asked for their consent to be contacted by the research team about the study.

Method 2: Women will also be identified from ultrasound scan clinics where they will be given study information, eligibility screening questions (EPDS) and a form to indicate their willingness to be contacted by the research team for assessment if screening positive (EPDS 10 or above). This approach will provide a good opportunity to recruit disadvantaged groups, as attendance at scanning clinics does not appear to be socially patterned.<sup>31</sup> Where needed, interpreters will be used to ensure that those who do not have English as a first language can be offered therapy.

Figure 1 shows the flow of participants through the trial.

### Assessment and randomisation.

A researcher will conduct a telephone assessment with women who consent to be contacted. At a subsequent face to face meeting the researcher will establish eligibility for

1  
2  
3 the trial, obtain written consent and collect baseline data. Partners will also be asked for their  
4 consent either in person at the baseline visit, online or by post.

5  
6 Randomisation will be carried out remotely by Bristol Randomised Trials Collaboration  
7 randomisation service. It will be stratified by recruiting centre and minimised by parity (with  
8 random block sizes).  
9  
10

### 11 12 13 **Treatment arms**

14 We have embedded the treatments within existing psychological treatment services  
15 available in primary care (Improving Access to Psychological Therapies: IAPT). For women  
16 with mild or moderate depression during pregnancy considered suitable for a low intensity  
17 intervention, we will compare up to six sessions of either low intensity CBT or IPC.  
18  
19  
20  
21

### 22 **Training and supervision for practitioners**

23 To avoid potential selection bias, 12 psychological wellbeing practitioners will be  
24 randomised, six to be trained in IPC and six to continue delivering low intensity CBT.  
25  
26  
27

28 IAPT low intensity (brief therapy) practitioners who agreed to take part in the study and are  
29 randomised to the IPC group will receive three days of training from RL (co-applicant; chair  
30 of Interpersonal Therapy (IPT) UK; experienced, certified IPT/IPC trainer). Supervisors for  
31 the practitioners, who are already trained in IPT (the model from which IPC is derived) will  
32 attend the training days. The practitioners will be required to audio record cases, which will  
33 be assessed by their supervisor to ensure competence and fidelity to the model. Supervision  
34 will be provided weekly initially, and then fortnightly once practitioners are more familiar with  
35 IPC. Those delivering the six sessions of CBT will be given refresher training and have  
36 fortnightly case supervision as is usual practice for CBT. Supervisors will rate adherence  
37 from a checklist and feedback to trainees. These ratings will be used to assess fidelity.  
38  
39  
40  
41  
42  
43  
44  
45

### 46 **Data Collection and management**

47 All data collected and analysed during the study will be pseudo-anonymised using a unique  
48 identifier. A record of trial participants' names and contact details and assigned trial numbers  
49 will be maintained by the trial coordinator and stored separately and securely for  
50 administrative purposes. Study data collected by the research team will be recorded on  
51 study specific data collection forms (CRFs). Data will then be entered onto a REDCap  
52 database.  
53  
54  
55  
56  
57  
58  
59  
60

### Baseline Measurements

Baseline data will be collected at an initial face-to-face assessment with women and will include measures of mood, quality of life, quality of relationship with partner and antenatal attachment. Partners will also be invited to complete a depression rating scale.

### Follow-up Measurements

Assessments will be completed either online by participants or over the telephone with a researcher 12 weeks following randomisation. This allows time for women to be allocated to therapy and to complete the sessions. Non-responders will receive two automatic online or telephone reminders one week apart, with attempts to collect data by telephone a week later if necessary.

### Measures at baseline and 12-weeks

- 1) CIS-R a computerised structured psychiatric interview (at baseline only)
- 2) Edinburgh Postnatal Depression Scale (EPDS)<sup>32</sup> continuous and binary scores from women and their partners. The scale, sometimes known as the Edinburgh Depression Scale, was developed for postnatal depression but is widely used during pregnancy and has been validated outside the postnatal period and for men.<sup>33, 34</sup>
- 3) The Revised Dyadic Adjustment Scale<sup>35</sup> assesses partner satisfaction.
- 4) Maternal Antenatal Attachment Scale.<sup>36</sup>
- 5) Health economic measures outlined below (EQ-5D-5L, ReQoI10).
- 6) At 12-weeks only: The number of sessions attended, number that include the partner, whether step up to more intense psychological intervention is needed, use of medication, and use of secondary mental health services.

### Blinding

It will not be possible for assessors or participants to be blind to allocation however the statistician will be blind to allocation of participants.

### Outcomes

The primary outcome will be the proportion of eligible women successfully recruited to the point of randomisation.

We will assess numbers and proportions of participants:

- Recruited for assessment (comparing two methods of recruitment),
- Randomised
- Completing the course of treatment

- Completing follow up measures
- Requiring 'step up' to a higher intensity intervention.

We will assess the acceptability of the recruitment method, intervention and study design through a series of in-depth interviews with participants and IAPT practitioners.

The primary outcome for a future trial is likely to be change in EPDS score but we will also consider the other secondary outcomes collected in this trial.

### **Sample size determination.**

As this is a feasibility study, the sample size should be sufficient to measure feasibility parameters and data completeness with adequate precision.

There are around 3000 pregnancies per year at site A and 1500 at site B (total 4500) in the relevant IAPT catchment areas, giving a total of approximately 3375 pregnancies in the nine-month recruitment period. Assuming 10% of these have mild-moderate antenatal depression (338) and recruiting through both midwives booking appointments and ultrasound scanning clinics we aim to include 60 women. This target of 60 subjects from 338 potentially eligible women (17.8%) gives a 95% confidence interval for recruitment between 13.9% and 22.3%

### **Economic evaluation**

A full economic evaluation is not possible based on the results of this feasibility study. Within the feasibility study we assess whether and how necessary data can be collected. We will pilot methods for collecting resource use data in this population and use the results to plan the future main trial. Intervention delivery resource will be recorded.

The main economic outcome measure collected will be the EQ-5D-5L, a generic preference-based measure of health.<sup>37</sup> Recognising that non-health dimensions of wellbeing were important to our PPI group, we will also collect data on the ReQoL10 instrument, an alternative preference-based outcome tool that includes domains beyond health and has been developed specifically for use in groups with mental health problems ([www.requol.org.uk](http://www.requol.org.uk)). Resource use data will be collected online or by telephone as part of the 12-week follow-up. We will ask participants to report resource use during the time enrolled on the study.

### **Qualitative study.**

We will collect qualitative data through interviews to assist in determining the feasibility and acceptability of the intervention and trial design. We will explore the acceptability of the intervention to women receiving IPC and CBT; the feasibility of recruitment and follow up.

We will conduct semi-structured interviews either face to face or on the phone. It is anticipated interviews will last between 30 minutes and 1 hour. Topic guides will be informed by the research literature, team discussions and input from PPI. We will interview the following groups:

#### *A) Women in the treatment arms.*

These will be conducted at the completion of either IPC (10-12 women) or CBT (5-6 women). Purposive maximum variation sampling will ensure that women from different age groups, socioeconomic status, ethnicity and different levels of engagement with the intervention are selected from both study sites. Interviews will focus on the acceptability and perceived effectiveness of the talking therapy and explore views on the recruitment process; helpful and challenging aspects of the intervention; and the appropriateness of the outcome measures being used.

#### *B) Partners (or significant others) of those receiving IPC or CBT.*

Interviews will be conducted with 5 or 6 partners focusing on the acceptability and perceived effectiveness of the intervention and explore ways they feel their partners have benefited from the talking therapy.

#### *C) Participants who drop out.*

We will seek the views of participants who withdrew or did not attend the intervention to understand their reasons for dropping out and whether continuing participation (and engagement in the intervention) could be supported. These will be short telephone interviews and we would attempt to contact them up to three times.

#### *D) Staff interviews.*

Interviews (6-8) with practitioners in the IPC arm, their supervisors and community midwives, will be carried out at the end of the intervention and focus on the acceptability, strengths and weaknesses of the intervention.

## Data Analyses

### Quantitative Data analysis

As this is a feasibility trial no formal statistical testing will be carried out. Instead the analysis will focus on reporting data that will be used for planning and for assessing the feasibility of the full trial.

A CONSORT flow diagram will be produced. Proportions with 95% confidence intervals calculated using the Exact Binomial Method will be produced for:

- Participants consented.
- Participants who are randomised with completed baseline measures.
- Participants randomised to IPC who complete it.
- Participants randomised to low intensity CBT who complete it.
- Randomised participants lost to follow-up.
- Randomised participants who require 'step up' to a higher intensity intervention.
- Randomised participants who have complete outcome data.

Baseline characteristics and demographic characteristics will be tabulated by treatment group (defined by intention to treat) and overall. Means or medians together with appropriate measures of dispersion will be reported for continuous measures and proportions for binary measures. The follow-up outcome data (namely the EPDS, Revised Dyadic Adjustment Scale, Maternal Antenatal Attachment Scale, number of sessions attended, number of sessions partner attended, medication use and secondary health service use) will be reported in the same way. Plots will be used to examine the distribution of continuous outcomes.

### Qualitative data analysis

All interviews will be audio-recorded, transcribed verbatim and anonymised. Thematic analysis methods<sup>38</sup> will be used with NVivo to aid data management. Interview transcripts will be read and re-read individually, from which an initial coding framework will be developed. Team members will meet to discuss the preliminary coding framework and themes to ensure that the emerging analysis is trustworthy and credible. This framework will be added to and refined, with coded material regrouped as new data from subsequent interviews are gathered.

### **Patient and public involvement / Patient Advisory Group (PAG)**

Discussions with women who have perinatal mental health problems and are currently using services, colleagues running voluntary sector perinatal mental health services and feedback from public engagement events, have all highlighted the need to improve psychological treatment services available to women and their partners during pregnancy and following childbirth. We asked women attending an antenatal group for those with mental health problems in pregnancy what they thought would have helped them most and they highlighted the need for a therapy that is more specific to pregnant women. Some reported that current treatment offered (CBT) was 'too clinical' and those providing the treatment made little reference to pregnancy or worries about coping with a young baby. We have two collaborators who run voluntary sector organisations providing help to women with mental health problems during the perinatal period. One has been involved in the development of the ideas surrounding this and the other has been providing advice about women's experience of local psychological treatment services, as well as commenting on the proposal and several aspects of the design. At two public engagement events held in Bristol we discussed services for families and how these could be improved. At one event for fathers whose partners struggled with their mood and anxiety during pregnancy or following child birth they gave a clear message that they felt excluded and even treated with suspicion by services. Fathers welcomed any psychological treatment which might include them and focus on improving the relationship with their partner. Six women who have been attending either an antenatal group aimed at promoting emotional wellbeing or postnatal drop-in sessions run by the voluntary sector, have agreed to form a Patient Advisory Group (PAG) meeting three times during the study.

The PAG members will assist in the development of patient facing materials, advise on recruitment issues, inform the development of the topic guide for the qualitative interviews and discuss and help interpret the results including the decision on whether to proceed to a full trial. They will be offered a study specific induction pack which will include the INVOLVE materials and relevant study information. Training workshops run by People and Research West of England will also be offered to them. PAG members will have their travel expenses and meeting time reimbursed with vouchers. Our findings will be presented in lay terms at a PAG meeting and they will advise us on routes for dissemination to patient groups.



## ETHICS, MONITORING AND DISSEMINATION

This manuscript is based on Protocol V.3.0 dated 21/06/2019. The study received North of Scotland Research Ethics Committee (REC) approval on October 29<sup>th</sup> 2018 and Health Research Authority approval on November 14<sup>th</sup> 2018. The trial will be conducted in accordance with the protocol, the principles of the Declaration of Helsinki and ICH GCP. Any amendments of the protocol will be submitted to the REC for approval. On request, the study investigators and their institutions will permit trial-related monitoring and audits by the Sponsor and relevant Research Ethics Committee by providing direct access to source data and other documents (i.e. patients' hospital notes).

A Trial Steering Committee (TSC) has been convened to provide overall supervision of the trial and ensure it is in accordance with the principles of good clinical practice and relevant regulations. The TSC agreed the trial protocol and will agree any protocol amendments. The TSC also provide advice to the investigators on all aspects of the trial including aspects of safety and monitoring of serious adverse events. The TSC is chaired by Prof Paul Ramchandani with three independent members who have expertise in clinical psychology and perinatal mental health, midwifery for NHS England, and statistics.

### Dissemination.

A lay summary of the study is available on the NIHR website. Results of this feasibility study will be publicly available through open access publication in a peer-reviewed journals and presented at relevant conferences and research meetings. The PPI groups will contribute to the dissemination plan and assist in the production of the lay summaries.

Word count 3957

**Acknowledgements** The authors would like to thank the lay representatives who contribute to the trial management and steering groups and the women who contributed to the intervention design.

**Author Contributions:** JE is the chief investigator and JI drafted the paper with critical input from all authors. All authors contributed to study design and development. JE, JI, HO'M, DK, HT, JR, RL, IC and JF contributed to the inception of the study. All authors read, commented on and approved the final manuscript.

**Funding:** This work is supported by the National Institute for Health Research (NIHR) Research for Patient Benefit research programme grant number PB-PG-1216-20027.

**Disclaimer:** The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

**Competing interests:** None

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data sharing statement:** The results of this feasibility study will inform the planning of a definitive randomised controlled trial, including whether it can be conducted, by assessing rates of recruitment, retention and data collection.

**Trial status:** Ongoing data collection.

**Trial sponsor:** University of Bristol. Bristol BS1 5DD: [research-governance@bristol.ac.uk](mailto:research-governance@bristol.ac.uk)

## REFERENCES.

1. Howard, L.M., Ryan, E.G., Trevillion, K., Anderson, F., Bick, D., Bye, A. et al. (2018). Accuracy of the Whooley questions and the Edinburgh Postnatal Depression Scale in identifying depression and other mental disorders in early pregnancy. *British Journal of Psychiatry*, 212: 50-56.
2. Gavin, N. I., Gaynes, B. N., Lohr, K. N., Meltzer-Brody, S., Gartlehner, G., & Swinson, T. (2005). Perinatal depression: a systematic review of prevalence and incidence. *Obstetrics & Gynecology*, 106(5, Part 1), 1071-1083.
3. Grigoriadis, S., Vonderporten, E.H., Mamisashvili, L., Tomlinson, G., Dennis, C.L., Koren, G. et al. (2013). The impact of maternal depression during pregnancy on perinatal outcomes: A systematic review and meta-analysis. *Journal of Clinical Psychiatry*, 74(4): 321
4. Pedersen, L.H., Henriksen, T.B. and Olsen, J. (2010) Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. *Pediatrics*, 125(3): 600-608
5. Madigan, S., Oatley, H., Racine, N., Fearon, R.M.P., Schumacher, L., Akbari, E. et al. (2018). A meta-analysis of maternal prenatal depression and anxiety on child socioemotional development. *Journal of the American Academy of Child and Adolescent Psychiatry*, 57(9): 645
6. Cohen, L.S., Altschuler, L.L., Harlow, B.L., Nonacs, R., Newport, D.J., Viguera, A.C. et al. (2006). Relapse of major depression during pregnancy in women who maintain or

- 1  
2  
3 discontinue antidepressant treatment. *Journal of the American Medical Association*, 295(5):  
4 499-507.  
5  
6  
7 7. NICE Clinical guideline 192 (2014) Antenatal and postnatal mental health: clinical  
8 management and service guidance.  
9  
10 8. Bosanquet, K., Bailey, D., Gilbody, S., Harden, M., Manea, H., Nutbrown, S. and  
11 McMillan, D. (2015). Diagnostic accuracy of the Whooley questions for the identification of  
12 depression: A diagnostic meta-analysis. *British Medical Journal Open*. 5(12)  
13  
14 9. Darwin, Z., McGowan, L. and Edozien, L.C. (2015). Antenatal mental health referrals:  
15 Review of local clinical practice and pregnant women's experiences in England. *Midwifery*,  
16 31(3): 17-22  
17  
18 10. Dennis, C. L., Ross, L. E., & Grigoriadis, S. (2007). Psychosocial and psychological  
19 interventions for treating antenatal depression. *Cochrane Database of Systematic Reviews*  
20 2007, Issue 3. Art. No.: CD006309. DOI: 10.1002/14651858.CD006309.pub2.  
21  
22 11. Arch, J.J. (2014). Cognitive behavioral therapy and pharmacotherapy for anxiety:  
23 Treatment preferences and credibility among pregnant and non-pregnant women.  
24 *Behaviour Research and Therapy* 52:53-60  
25  
26 12. Hayes, R.M., Wu, P.S., Shelton, R.C., Cooper, W.O., Dupont, W.D., Mitchel, E. and  
27 Hartert, T.V. (2012) Maternal antidepressant use and adverse outcomes: A cohort study of  
28 228876 pregnancies. *American Journal of Obstetrics and Gynecology*, 207(1)  
29  
30 13. Bilszta, J.L.C., Tsuchiya, S., Han, K., Buist, A.E., Einarson, A. (2011). Primary care  
31 physicians' attitudes and practices regarding antidepressant use during pregnancy: A survey  
32 of two countries. *Archives of Womens Mental Health*. 14(1): 71-75  
33  
34 14. Chisolm, M.S. and Payne, J.L. (2016) Management of psychotropic drugs during  
35 pregnancy. *British Medical Journal*, 352:h5918  
36  
37 15. Sockol, L. E., Epperson, C. N., & Barber, J. P. (2011). A meta-analysis of treatments for  
38 perinatal depression. *Clinical Psychology Review*, 31(5), 839-849.  
39  
40 16. Beck, A.T. (1967) *Depression: Clinical, Experimental, and Theoretical Aspects*. New  
41 York: Harper & Row.  
42  
43 17. Johansen, S.L., Robakis, T.K., Williams, K.E. and Rasgon, N.L. (2019) Management of  
44 perinatal depression with non-drug interventions. *British Medical Journal*, 364:l322.  
45  
46 18. Cox, E.Q., Sowa, N.A., Meltzer-Brody, S.E. and Gaynes, B.N. (2016) The perinatal  
47 depression treatment cascade: Baby steps toward improving outcomes. *Journal of Clinical*  
48 *Psychiatry*, 77(9):1189-1200.  
49  
50 19. Ravitz, P., Watson, P., Lawson, A., Contatino, M.J., Bernecker, S., Park, J. and Swartz,  
51 H.A. (2019) Interpersonal psychotherapy: A scoping review and historical perspective  
52 (1974-2017). *Harvard Review of Psychiatry*. Accessed online via PMID 30883446.  
53  
54 20. Lipsitz, J. D., & Markowitz, J. C. (2013). Mechanisms of change in interpersonal therapy  
55 (IPT). *Clinical psychology review*, 33(8), 1134-1147.  
56  
57  
58  
59  
60

- 1  
2  
3 21. Lancaster, C. A., Gold, K. J., Flynn, H. A., Yoo, H., Marcus, S. M., & Davis, M. M. (2010).  
4 Risk factors for depressive symptoms during pregnancy: a systematic review. *American*  
5 *Journal of Obstetrics and Gynecology*, 202(1), 5-14.  
6  
7 22. NHS Digital 2016: Psychological Therapies: Annual Report on the use of IAPT services,  
8 England, 2015-16  
9  
10 23. Menchetti, M., Rucci, P., Bortolotti, B., Bombi, A., Scocco, P., Kraemer, H. C., Berardi D,  
11 DEPICS group. (2013). Moderators of remission with interpersonal counselling or drug  
12 treatment in primary care patients with depression: randomised controlled trial. *The British*  
13 *Journal of Psychiatry*. 204(2): 144-150.  
14  
15 24. Wilkinson PO, Cestaro V, Pinchen I. Pilot mixed-methods evaluation of interpersonal  
16 counselling for young people with depressive symptoms in non-specialist services  
17 *Evidence-Based Mental Health* 2018;21:134-138.  
18  
19 25. Lenze, Shannon N., and Mary Anne Potts. (2017) Brief Interpersonal Psychotherapy for  
20 depression during pregnancy in a low-income population: A randomized controlled trial  
21 *Journal of Affective Disorders* 210: 151-157.  
22  
23 26. Stuart, S. (2012). Interpersonal psychotherapy for postpartum depression. *Clinical*  
24 *Psychology & Psychotherapy*, 19(2), 134-140.  
25  
26 27. Bauer, A., Parsonage, M., Knapp, M., Lemmi, V., & Adelaja, B. (2014). Costs of perinatal  
27 mental health problems. *London School of Economics and Political Science*.  
28  
29 28. Lewis G, Pelosi AJ, Araya R, Dunn G: (1992) Measuring psychiatric-disorder in the  
30 community – a standardized assessment for Use by Lay interviewers. *Psychol Med*. 22 (2):  
31 465-486.  
32  
33 29. Burns, A., O'Mahen, H., Baxter, H., Bennert, K., Wiles, N., Ramchandani, P., ... & Evans,  
34 J. (2013). A pilot randomised controlled trial of cognitive behavioural therapy for antenatal  
35 depression. *BMC Psychiatry*, 13(1), 33.  
36  
37 30. Wilkinson, E. L., O'Mahen, H. A., Fearon, P., Halligan, S., King, D. X., Greenfield, G., ...  
38 & Ramchandani, P. G. (2016). Adapting and testing a brief intervention to reduce maternal  
39 anxiety during pregnancy (ACORN): study protocol for a randomised controlled trial. *Trials*,  
40 17(1), 156.  
41  
42 31. Redshaw, M., & Henderson, J. (2013). Fathers' engagement in pregnancy and childbirth:  
43 evidence from a national survey. *BMC Pregnancy and Childbirth*, 13(1), 70.  
44  
45 32. Cox, J. L., Holden, J. M., & Sagovsky, R. (1987). Detection of postnatal depression.  
46 Development of the 10-item Edinburgh Postnatal Depression Scale. *The British Journal of*  
47 *Psychiatry*, 150(6), 782-786.  
48  
49 33. Hewitt C, Gilbody S, Brealey S, et al. (2009) Methods to identify postnatal depression in  
50 primary care: an integrated evidence synthesis and value of information analysis. *Health*  
51 *Technol Assess*. 13(36):1-145, 147-230.  
52  
53 34. Edmondson OJ, Psychogiou L, Vlachos H, Netsi E, Ramchandani PG. (2010)  
54 Depression in fathers in the postnatal period: assessment of the Edinburgh Postnatal  
55 Depression Scale as a screening measure. *J Affect Disord*. 125(1-3):365-368.  
56  
57  
58  
59  
60

- 1  
2  
3 35. Busby DM, Christensen C, Crane DR, Larson JH. (1995). A revision of the dyadic  
4 adjustment scale for use with distressed and nondistressed couples: construct hierarchy and  
5 multidimensional scales. *Journal of Marital and Family Therapy*; 21(3):289-308.  
6  
7 36. Condon JT. (1993) The assessment of antenatal emotional attachment: development of  
8 a questionnaire instrument. *Br J Med Psychol*; 66 (Pt 2): 167-183  
9  
10 37. Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonse, G., Badia,  
11 X. (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-  
12 5D-5L) *Quality of Life Research*, 20(10), pp1727-1736.  
13  
14 38. Braun, V., & Clarke, V. (2006), Using thematic analysis in psychology. *Qualitative*  
15 *Research in Psychology*, 3, 77-101.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

FIGURE 1. STUDY FLOW DIAGRAM




Figure 1. Study flow diagram

239x246mm (72 x 72 DPI)



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	__ 1 __
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	__ 2 __
	2b	All items from the World Health Organization Trial Registration Data Set	_____
Protocol version	3	Date and version identifier	__ 15 __
Funding	4	Sources and types of financial, material, and other support	__ 16 __
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	__ 15 __
	5b	Name and contact information for the trial sponsor	__ 16 __
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	_____
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	__ 15 __

## 1 Introduction

2			
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant
4	rationale		studies (published and unpublished) examining benefits and harms for each intervention
5			
6		6b	Explanation for choice of comparators
7			
8	Objectives	7	Specific objectives or hypotheses
9			
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),
11			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
12			
13			

## 14 Methods: Participants, interventions, and outcomes

15			
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will
17			be collected. Reference to where list of study sites can be obtained
18			
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and
20			individuals who will perform the interventions (eg, surgeons, psychotherapists)
21			
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be
23			administered
24		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose
25			change in response to harms, participant request, or improving/worsening disease)
26		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence
27			(eg, drug tablet return, laboratory tests)
28		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
29			
30			
31			
32	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood
33			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,
34			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen
35			efficacy and harm outcomes is strongly recommended
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			



1	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	_8-11_____
2				
3				
4	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	_11_____
5				
6				
7	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	_8_____
8				
9				
10	<b>Methods: Assignment of interventions (for controlled trials)</b>			
11	Allocation:			
12				
13	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	_9_____
14				
15				
16				
17				
18				
19	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	_9_____
20				
21				
22				
23				
24	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	_8-9_____
25				
26				
27	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	_10__
28				
29				
30		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	_na_____
31				
32				
33				
34	<b>Methods: Data collection, management, and analysis</b>			
35				
36	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	_10-11__
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

1		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	__10__
2				
3				
4	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	__9__
5				
6				
7				
8	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	__13__
9				
10				
11		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	__na__
12				
13		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	_____
14				
15				
16				
17	<b>Methods: Monitoring</b>			
18				
19	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	__15__
20				
21				
22				
23				
24				
25		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	__na__
26				
27				
28	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	_____
29				
30				
31	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	_____
32				
33				
34				
35	<b>Ethics and dissemination</b>			
36				
37	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	__15__
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Protocol	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes,	___15___
2	amendments		analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals,	
3			regulators)	
4				
5	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and	8-9___
6			how (see Item 32)	
7				
8		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary	___na___
9			studies, if applicable	
10				
11	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained	___9___
12			in order to protect confidentiality before, during, and after the trial	
13				
14	Declaration of	28	Financial and other competing interests for principal investigators for the overall trial and each study site	___16___
15	interests			
16				
17				
18	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that	___
19			limit such access for investigators	
20				
21	Ancillary and post-	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial	___
22	trial care		participation	
23				
24	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, health care professionals,	___15___
25			the public, and other relevant groups (eg, via publication, reporting in results databases, or other data	
26			sharing arrangements), including any publication restrictions	
27				
28				
29		31b	Authorship eligibility guidelines and any intended use of professional writers	___na___
30				
31		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	___16___
32				
33	<b>Appendices</b>			
34				
35	Informed consent	32	Model consent form and other related documentation given to participants and authorised surrogates	___
36	materials			
37				
38	Biological	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular	___na___
39	specimens		analysis in the current trial and for future use in ancillary studies, if applicable	
40				
41				
42				
43				
44				
45				
46				

1 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
2 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
3 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

For peer review only

bmjopen-2019-032649 on 18 August 2019. Downloaded from <http://bmjopen.bmj.com/> on April 27, 2024 by guest. Protected by copyright.

# BMJ Open

## Protocol for a feasibility randomised trial of low intensity interventions for antenatal depression: ADAGIO trial comparing Interpersonal Counselling with Cognitive Behavioural Therapy.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032649.R1
Article Type:	Protocol
Date Submitted by the Author:	05-Jul-2019
Complete List of Authors:	Ingram, Jenny; University of Bristol, Bristol Medical School, Centre for Academic Child Health Johnson, Debbie; University of Bristol, Bristol Medical School, Centre for Academic Child Health Johnson, Sarah; University Hospitals Bristol NHS Foundation Trust O'Mahen, Heather; University of Exeter Kessler, David; University of Bristol, Taylor, Hazel; University Hospitals Bristol NHS Foundation Trust Law, Roslyn; Anna Freud Centre Round, Jeff; Institute of Health Economics Ford, Jenny Hopley, Rebecca; University of Exeter Glynn, Joel; University of Bristol Culpin, I; University of Bristol, Bristol Medical School Evans, Jonathan; University Of Bristol, Bristol Medical School
<b>Primary Subject Heading</b>:	Mental health
Secondary Subject Heading:	Mental health
Keywords:	MENTAL HEALTH, Depression & mood disorders < PSYCHIATRY, Pregnancy

SCHOLARONE™  
Manuscripts

1  
2  
3 **Protocol for a feasibility randomised trial of low intensity interventions for antenatal**  
4 **depression: ADAGIO trial comparing Interpersonal Counselling with Cognitive**  
5 **Behavioural Therapy.**  
6

7 Jenny Ingram<sup>1</sup>,

8  
9 Debbie Johnson<sup>1</sup>,

10 Sarah Johnson<sup>2</sup>,

11  
12 Heather O'Mahen<sup>3</sup>,

13  
14 David Kessler<sup>4</sup>,

15  
16 Hazel Taylor<sup>5</sup>,

17 Roslyn Law<sup>6</sup>,

18  
19 Jeff Round<sup>7</sup>,

20  
21 Jenny Ford<sup>2</sup>,

22  
23 Becky Hopley<sup>3</sup>,

24  
25 Joel Glynn<sup>8</sup>,

26  
27 Iryna Culpin<sup>4</sup>,

28  
29 Jonathan Evans<sup>4</sup>

30  
31 <sup>1</sup> Centre for Academic Child Health, Bristol Medical School, University of Bristol, UK.

32  
33 <sup>2</sup> University Hospitals NHS Foundation Trust, Bristol, UK

34  
35 <sup>3</sup> Department of Psychology, University of Exeter, UK

36  
37 <sup>4</sup> Centre for Academic Mental Health, Bristol Medical School, University of Bristol, UK.

38  
39 <sup>5</sup> Research Design Service- South West, University Hospitals NHS Foundation Trust, Bristol,  
40 UK

41  
42 <sup>6</sup> Anna Freud National Centre for Children and Families, London, UK

43  
44 <sup>7</sup> Institute of Health Economics, Alberta, Canada; and Health Economics Bristol, University  
45 of Bristol, UK

46  
47 <sup>8</sup> Health Economics Bristol, Bristol Medical School, University of Bristol, UK

48  
49  
50  
51 Corresponding author: Dr Jenny Ingram, Centre for Academic Child Health, University of  
52 Bristol, Bristol Medical School, 1-5 Whiteladies Road, Bristol BS8 1NU. 0117 428 3095;

53  
54  
55 Email: [jenny.ingram@bristol.ac.uk](mailto:jenny.ingram@bristol.ac.uk).

## ABSTRACT

**Introduction.** One in eight women suffer from depression during pregnancy. Currently low intensity brief treatment based on cognitive behavioural therapy (CBT) is the only talking treatment widely available in the NHS for mild and moderate depression. CBT involves identifying and changing unhelpful negative thoughts and behaviours to improve mood. Mothers in our patient advisory groups requested greater treatment choice. Interpersonal counselling (IPC) is a low intensity version of interpersonal therapy. It may have important advantages during pregnancy over CBT because it targets relationship problems, changes in role and previous losses (e.g. miscarriage). We aim to compare CBT and IPC for pregnant women with depression in a feasibility study.

**Methods and analysis:** A two-arm non-blinded randomised feasibility study of 60 women will be conducted in two UK localities. Women with depression will be identified through midwife clinics and ultrasound scanning appointments and randomised to receive six sessions of IPC or CBT. In every other way these women will receive usual care. Women thought to have severe depression will be referred for more intensive treatment. After 12 weeks we will measure women's mood, well-being, relationship satisfaction and use of health care. Women, their partners and staff providing treatments will be interviewed to understand whether IPC is an acceptable approach and whether changes should be introduced before applying to run a larger trial.

Several groups of patients with depression during pregnancy have contributed to our study design. A patient advisory group will meet and advise us during the study.

**Ethics and dissemination:** Study results will inform the design of a larger multicentre RCT. Our findings will be shared through public engagement events, papers and reports to organisations within the NHS. National Research Ethics Service Committee approved the study protocol.

Trial registration number: ISRCTN 11513120

1  
2  
3 **Article summary.**  
4

5 **Strengths and limitations of the study.**  
6  
7

- 8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30
- This study uses a two-centre randomised controlled trial design to determine the feasibility of a definitive trial.
  - Two methods of identifying participants will be used: through community midwives at booking and through ultrasound scanning clinics.
  - Two talking therapies will be offered to assess the acceptability of these interventions during pregnancy.
  - A process evaluation will explore the fidelity of intervention delivery and the experience of women, partners (or a significant other) and therapists.
  - A definitive trial would be necessary to evaluate the effectiveness of the intervention.

31 Key words: Antenatal depression; Cognitive behavioural therapy; interpersonal counselling.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## INTRODUCTION.

Antenatal depression is common, with a reported prevalence of 11%<sup>1</sup> and a point prevalence of up to 44% in certain populations.<sup>2</sup> Antenatal depression is associated with a range of poor outcomes including continuing depression into the postnatal period, reduced breastfeeding rates<sup>3</sup>, infant developmental delay<sup>4</sup>, and social/emotional problems, including depression in the offspring during adolescence.<sup>5</sup> Pregnancy does not appear to be protective against developing depression or relapsing in those with a previous history of depression.<sup>6</sup>

Currently, the Whooley questions are used to identify women who may have antenatal depression.<sup>7</sup> This screening method has high sensitivity (95%) and modest specificity (65%) for antenatal depression.<sup>8</sup> However, anecdotal evidence suggests that women are not always aware that they are referred for further help following a positive Whooley screen.<sup>9</sup>

There is limited evidence for the effectiveness of psychological interventions for antenatal depression<sup>10</sup>, despite a widespread reluctance of mothers to take antidepressants during pregnancy<sup>11</sup> with 75% of women discontinuing antidepressant medication in the first trimester.<sup>12</sup> There is also concern amongst clinicians about prescribing antidepressant medication<sup>13</sup>, largely due to a lack of evidence regarding their safety<sup>14</sup>, indicating that psychological interventions are particularly important at this time.<sup>10,15</sup> One study found that women who discontinue antidepressant medication during pregnancy are five times more likely to experience a relapse in their depression requiring treatment.<sup>6</sup> The current treatment recommendation for mild to moderate depression, including depression that occurs during pregnancy, is a brief, one to one supported self-help approach using the principles of cognitive behavioural therapy (CBT) known as low intensity CBT.

### *Theoretical basis of CBT and limitations for this population.*

The theoretical basis of CBT is that individuals prone to depression hold dysfunctional beliefs and therefore see the world through a negative filter.<sup>16</sup> Adversity, such as pregnancy, triggers these underlying beliefs and prone individuals then behave in a way that is consistent with these negative beliefs thus triggering and reinforcing depression. There is no specific relevance of this model to pregnancy and it relies on the skill of the therapist to adapt CBT to individual circumstances. Although there is a growing evidence base for 'high intensity' CBT delivered by experienced therapists for perinatal depression, 'low intensity' CBT is briefer and delivered by less experienced practitioners who have limited scope to adapt to the perinatal context and be flexible in its use. The use of high intensity CBT is limited within current clinical frameworks due to limitations in funding and therapist

1  
2  
3 availability.CBT has few explicit strategies to manage many of the problems that are  
4 common for women with antenatal depression, including role transitions and problems in  
5 relationships.  
6  
7  
8

9  
10 A recent review highlighted the need for more personalized therapies to treat perinatal  
11 depression, including interpersonal psychotherapy as a plausible treatment option.<sup>17</sup> Women  
12 in our patient advisory group consultations reported that CBT is 'too clinical' and 'inflexible'  
13 with practitioners not appearing to consider the circumstances of pregnancy. This may be  
14 one reason why the uptake of CBT treatment for antenatal depression is low. It has been  
15 reported that 14% of women with antenatal depression receive psychological treatment and  
16 only 5% with antenatal depression achieve remission following treatment.<sup>18</sup> Women who are  
17 pregnant receive lower rates of psychological intervention than those outside the perinatal  
18 period (30% vs 50%) despite an increased need for psychological treatment rather than drug  
19 treatment at this time.  
20  
21  
22  
23  
24  
25

26  
27 *Theoretical basis of Interpersonal Counselling (IPC) and advantages for treating antenatal*  
28 *depression.*  
29

30 IPC is a brief treatment which may be more appropriate for addressing the problems that  
31 depressed women have during pregnancy and postnatally. It is derived from interpersonal  
32 therapy, which holds that interpersonal relationships are a basic human need and  
33 attachment to key individuals provides a secure base from which to manage stressful events  
34 and conditions.<sup>19</sup> Problems in interpersonal relationships can trigger symptoms of  
35 depression, such as low mood or sleeplessness, and these symptoms further compromise  
36 relationships leading to a downward spiral.<sup>20</sup> This is particularly relevant to pregnancy as  
37 conflict in relationships and poor social support are the strongest risk factors for antenatal  
38 depression.<sup>21</sup>  
39  
40  
41  
42  
43  
44  
45

46 IPC offers a more structured version of IPT that promotes understanding of depression  
47 through psychoeducation, problem solving and active involvement of the people in the  
48 person's life to provide support and promote recovery. IPC helps individuals develop useful  
49 strategies to manage interpersonal conflict and can involve the partner if appropriate. It also  
50 focuses on approaches that help manage changes in role, conflict, isolation and loss (i.e.,  
51 miscarriage, still-birth, termination, previous loss of would be grandparents) and the impact  
52 of these on relationships. By directly approaching these issues, IPC addresses what is  
53 theoretically central to depression and what service users report are significant worries and  
54 concerns for them. The approach is simple and focused and could be provided by  
55 practitioners who have limited training or experience.  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 Currently there are limited data on the effectiveness of IPC.<sup>14</sup> It is critical to test its  
6 effectiveness because although almost half (43%, n=201,591 in 2015-16) of all individuals  
7 who receive a talking treatment in the NHS will receive a brief, “low-intensity” treatment,  
8 interpersonal brief treatment approaches are currently not available in the NHS.<sup>22</sup>  
9  
10

11  
12 IPC has been clearly developed and rigorously manualised as an intervention allowing  
13 assessment of fidelity to the model. Although there have been very few studies of the  
14 effectiveness of IPC, and none in the UK, one study of depression in primary care in Italy  
15 found IPC to be more effective than antidepressants (SSRIs) particularly for those with less  
16 severe depression.<sup>23</sup> and a small UK pilot study found that IPC is an effective and  
17 acceptable treatment for young people with primarily depressive symptoms.<sup>24</sup> A small  
18 feasibility study of IPC for antenatal depression in the US amongst low income mothers  
19 indicated high satisfaction with IPC and some improvement in mood.<sup>25</sup>  
20  
21  
22  
23  
24  
25

26  
27 There are therefore good reasons to hypothesise that IPC may be more acceptable at this  
28 time and particularly effective in treating antenatal depression. There is some evidence that  
29 interpersonal therapy (IPT), a high intensity therapy from which IPC is derived, is more  
30 acceptable than 'high intensity' CBT, with sessions more likely to be attended and that  
31 outcomes are better for IPT than 'high intensity' CBT in existing psychological treatment  
32 services.<sup>22</sup> We argue that evaluating this intervention for treating antenatal depression is  
33 particularly important because:  
34  
35  
36  
37

- 38 1) the model is particularly relevant to pregnancy and therefore the advantages of this  
39 approach over standard CBT treatment may be greater than at other times.<sup>26</sup>
- 40 2) psychological treatment provision is a priority at this time because of the potential risks of  
41 antidepressants during pregnancy and the costs of depression during pregnancy.<sup>27</sup>  
42  
43  
44  
45

46 Training low-intensity practitioners in IPC has the potential to offer women an acceptable,  
47 empirically valid option which may prove to be more effective than CBT and provide the NHS  
48 with a treatment option that may be both effective and cost-effective.  
49  
50  
51

## 52 **AIMS and OBJECTIVES.**

53  
54  
55 Our overall aim is to improve psychological treatment for depression during pregnancy in  
56 order to improve outcomes for the mother, infant and the wider family. We aim to test  
57 whether six sessions of IPC are acceptable, effective and cost effective for treating mild to  
58 moderate antenatal depression compared to the most commonly provided existing  
59  
60

1  
2  
3 intervention, low intensity cognitive behavioural therapy (CBT). Both interventions are one to  
4 one therapies comprising up to six sessions.  
5  
6  
7

8 The aim of this first study is to establish the feasibility and acceptability of conducting a full  
9 scale randomised controlled trial to compare the effectiveness of these two low intensity  
10 interventions for antenatal depression. Using a pragmatic study design operating within the  
11 existing care pathway, we will explore whether a full-scale trial using such a design is  
12 feasible. Study objectives are shown in Box 1.  
13  
14  
15  
16

### 17 **Box 1: Detailed study objectives**

18 To determine whether a full trial is feasible by assessing:  
19

- 20  
21  
22 1) Whether staff who currently deliver low intensity interventions within routine  
23 psychological treatment services, known nationally as Improving Access to Psychological  
24 Treatment (IAPT) services, can reliably deliver this newly adapted therapy after brief,  
25 additional training.  
26  
27 2) Whether it is possible to recruit women from community midwife booking clinics and  
28 through screening at the ultrasound scanning clinics.  
29  
30 3) Whether it is feasible and acceptable to randomise women following assessment.  
31  
32 4) How acceptable IPC is to women, partners and those delivering the intervention relative  
33 to low intensity CBT, assessed through qualitative interviews.  
34  
35 5) Whether it is possible to collect sufficient outcome data, including those required to  
36 perform an economic evaluation.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 44 **METHODS AND ANALYSIS.**

### 46 **Study design.**

48 This feasibility study over 21 months will be carried out in two centres (site A and site B), in  
49 preparation for a pragmatic fully powered RCT. Women with mild to moderate depression  
50 during pregnancy considered suitable for a low intensity intervention will be randomised 1:1  
51 either to the usual low intensity treatment (CBT) or to a novel treatment called interpersonal  
52 counselling (IPC).  
53  
54  
55  
56  
57  
58  
59  
60

## Study population, setting and recruitment plan

Women who are aged 18 years or over are eligible for inclusion between 10 and 24 weeks of pregnancy, with an Edinburgh Depression Scale (EPDS) score 10 or above and mild or moderate depression according to Clinical Interview Schedule Revised (CIS-R)<sup>28</sup>, which gives an ICD-10 diagnosis, whether or not they are taking an antidepressant. Both primiparous and multiparous women will be eligible. Recruitment will continue for 9 months.

We will exclude women with psychotic illness, organic brain disorder, bipolar disorder, personality disorder, alcohol or substance dependency, which will be identified through self-report. Also excluded will be those judged to be at high suicide risk in assessor's judgement or from response to items on suicide in CIS-R or EPDS, those with severe depression according to CIS-R criteria, and those who have had CBT or IPT within the last 6 months. If women miscarry or have a termination during the trial, they will be offered the opportunity to continue with the treatment but will not be included in the rest of the study.

We will compare recruitment through two routes which have been used successfully in two previous trials of antenatal depression and antenatal anxiety:<sup>29, 30</sup>

Method 1: Women will be identified at community midwife booking clinics (around 8-10 weeks' gestation) through the routine screening undertaken for depression using the Whooley questions.<sup>8</sup> Those who answer 'yes' to either question and are considered by the midwife to be appropriate for further assessment for talking therapy, will be asked for their consent to be contacted by the research team about the study.

Method 2: Women will also be identified from ultrasound scan clinics where they will be given study information, eligibility screening questions (EPDS) and a form to indicate their willingness to be contacted by the research team for assessment if screening positive (EPDS 10 or above). This approach will provide a good opportunity to recruit disadvantaged groups, as attendance at scanning clinics does not appear to be socially patterned.<sup>31</sup> Where needed, interpreters will be used to ensure that those who do not have English as a first language can be offered therapy.

Figure 1 shows the flow of participants through the trial.

### Assessment and randomisation.

A researcher will conduct a telephone assessment with women who consent to be contacted. At a subsequent face to face meeting the researcher will establish eligibility for

1  
2  
3 the trial, obtain written consent and collect baseline data. Partners will also be asked for their  
4 consent either in person at the baseline visit, online or by post.

5  
6 Randomisation will be carried out remotely by Bristol Randomised Trials Collaboration  
7 randomisation service. It will be stratified by recruiting centre and minimised by parity (with  
8 random block sizes).  
9  
10

### 11 12 13 **Treatment arms**

14 We have embedded the treatments within existing psychological treatment services  
15 available in primary care (Improving Access to Psychological Therapies: IAPT). For women  
16 with mild or moderate depression during pregnancy considered suitable for a low intensity  
17 intervention, we will compare up to six sessions of either low intensity CBT or IPC.  
18  
19  
20  
21

### 22 **Training and supervision for practitioners**

23 To avoid potential selection bias, 12 psychological wellbeing practitioners will be  
24 randomised, six to be trained in IPC and six to continue delivering low intensity CBT.  
25  
26  
27

28 IAPT low intensity (brief therapy) practitioners who agreed to take part in the study and are  
29 randomised to the IPC group will receive three days of training from RL (co-applicant; chair  
30 of Interpersonal Therapy (IPT) UK; experienced, certified IPT/IPC trainer). Supervisors for  
31 the practitioners, who are already trained in IPT (the model from which IPC is derived) will  
32 attend the training days. The practitioners will be required to audio record cases, which will  
33 be assessed by their supervisor to ensure competence and fidelity to the model. Supervision  
34 will be provided weekly initially, and then fortnightly once practitioners are more familiar with  
35 IPC. Those delivering the six sessions of CBT will be given refresher training and have  
36 fortnightly case supervision as is usual practice for CBT. Supervisors will rate adherence  
37 from a checklist and feedback to trainees. These ratings will be used to assess fidelity.  
38  
39  
40  
41  
42  
43  
44  
45

### 46 **Data Collection and management**

47 All data collected and analysed during the study will be pseudo-anonymised using a unique  
48 identifier. A record of trial participants' names and contact details and assigned trial numbers  
49 will be maintained by the trial coordinator and stored separately and securely for  
50 administrative purposes. Study data collected by the research team will be recorded on  
51 study specific data collection forms (CRFs). Data will then be entered onto a REDCap  
52 database.  
53  
54  
55  
56  
57  
58  
59  
60

### Baseline Measurements

Baseline data will be collected at an initial face-to-face assessment with women and will include measures of mood, quality of life, quality of relationship with partner and antenatal attachment. Partners will also be invited to complete a depression rating scale.

### Follow-up Measurements

Assessments will be completed either online by participants or over the telephone with a researcher 12 weeks following randomisation. This allows time for women to be allocated to therapy and to complete the sessions. Non-responders will receive two automatic online or telephone reminders one week apart, with attempts to collect data by telephone a week later if necessary.

### Measures at baseline and 12-weeks

- 1) CIS-R a computerised structured psychiatric interview (at baseline only)
- 2) Edinburgh Postnatal Depression Scale (EPDS)<sup>32</sup> continuous and binary scores from women and their partners. The scale, sometimes known as the Edinburgh Depression Scale, was developed for postnatal depression but is widely used during pregnancy and has been validated outside the postnatal period and for men.<sup>33, 34</sup>
- 3) The Revised Dyadic Adjustment Scale<sup>35</sup> assesses partner satisfaction.
- 4) Maternal Antenatal Attachment Scale.<sup>36</sup>
- 5) Health economic measures outlined below (EQ-5D-5L, ReQoI10).
- 6) At 12-weeks only: The number of sessions attended, number that include the partner, whether step up to more intense psychological intervention is needed, use of medication, and use of secondary mental health services.

### Blinding

It will not be possible for assessors or participants to be blind to allocation however the statistician will be blind to allocation of participants.

### Outcomes

The primary outcome will be the proportion of eligible women successfully recruited to the point of randomisation.

We will assess numbers and proportions of participants:

- Recruited for assessment (comparing two methods of recruitment),
- Randomised
- Completing the course of treatment

- Completing follow up measures
- Requiring 'step up' to a higher intensity intervention.

We will assess the acceptability of the recruitment method, intervention and study design through a series of in-depth interviews with participants and IAPT practitioners.

The primary outcome for a future trial is likely to be change in EPDS score but we will also consider the other secondary outcomes collected in this trial.

### **Sample size determination.**

As this is a feasibility study, the sample size should be sufficient to measure feasibility parameters and data completeness with adequate precision.

There are around 3000 pregnancies per year at site A and 1500 at site B (total 4500) in the relevant IAPT catchment areas, giving a total of approximately 3375 pregnancies in the nine-month recruitment period. Assuming 10% of these have mild-moderate antenatal depression (338) and recruiting through both midwives booking appointments and ultrasound scanning clinics we aim to include 60 women. This target of 60 subjects from 338 potentially eligible women (17.8%) gives a 95% confidence interval for recruitment between 13.9% and 22.3%

### **Economic evaluation**

A full economic evaluation is not possible based on the results of this feasibility study. Within the feasibility study we assess whether and how necessary data can be collected. We will pilot methods for collecting resource use data in this population and use the results to plan the future main trial. Intervention delivery resource will be recorded.

The main economic outcome measure collected will be the EQ-5D-5L, a generic preference-based measure of health.<sup>37</sup> Recognising that non-health dimensions of wellbeing were important to our PPI group, we will also collect data on the ReQoL10 instrument, an alternative preference-based outcome tool that includes domains beyond health and has been developed specifically for use in groups with mental health problems ([www.requol.org.uk](http://www.requol.org.uk)). Resource use data will be collected online or by telephone as part of the 12-week follow-up. We will ask participants to report resource use during the time enrolled on the study.



### **Qualitative study.**

We will collect qualitative data through interviews to assist in determining the feasibility and acceptability of the intervention and trial design. We will explore the acceptability of the intervention to women receiving IPC and CBT; the feasibility of recruitment and follow up.

We will conduct semi-structured interviews either face to face or on the phone. It is anticipated interviews will last between 30 minutes and 1 hour. Topic guides will be informed by the research literature, team discussions and input from PPI. We will interview the following groups:

#### *A) Women in the treatment arms.*

These will be conducted at the completion of either IPC (10-12 women) or CBT (5-6 women). Purposive maximum variation sampling will ensure that women from different age groups, socioeconomic status, ethnicity and different levels of engagement with the intervention are selected from both study sites. Interviews will focus on the acceptability and perceived effectiveness of the talking therapy and explore views on the recruitment process; helpful and challenging aspects of the intervention; and the appropriateness of the outcome measures being used.

#### *B) Partners (or significant others) of those receiving IPC or CBT.*

Interviews will be conducted with 5 or 6 partners focusing on the acceptability and perceived effectiveness of the intervention and explore ways they feel their partners have benefited from the talking therapy.

#### *C) Participants who drop out.*

We will seek the views of participants who withdrew or did not attend the intervention to understand their reasons for dropping out and whether continuing participation (and engagement in the intervention) could be supported. These will be short telephone interviews and we would attempt to contact them up to three times.

#### *D) Staff interviews.*

Interviews (6-8) with practitioners in the IPC arm, their supervisors and community midwives, will be carried out at the end of the intervention and focus on the acceptability, strengths and weaknesses of the intervention.

## Data Analyses

### Quantitative Data analysis

As this is a feasibility trial no formal statistical testing will be carried out. Instead the analysis will focus on reporting data that will be used for planning and for assessing the feasibility of the full trial.

A CONSORT flow diagram will be produced. Proportions with 95% confidence intervals calculated using the Exact Binomial Method will be produced for:

- Participants consented.
- Participants who are randomised with completed baseline measures.
- Participants randomised to IPC who complete it.
- Participants randomised to low intensity CBT who complete it.
- Randomised participants lost to follow-up.
- Randomised participants who require 'step up' to a higher intensity intervention.
- Randomised participants who have complete outcome data.

Baseline characteristics and demographic characteristics will be tabulated by treatment group (defined by intention to treat) and overall. Means or medians together with appropriate measures of dispersion will be reported for continuous measures and proportions for binary measures. The follow-up outcome data (namely the EPDS, Revised Dyadic Adjustment Scale, Maternal Antenatal Attachment Scale, number of sessions attended, number of sessions partner attended, medication use and secondary health service use) will be reported in the same way. Plots will be used to examine the distribution of continuous outcomes.

### Qualitative data analysis

All interviews will be audio-recorded, transcribed verbatim and anonymised. Thematic analysis methods<sup>38</sup> will be used with NVivo to aid data management. Interview transcripts will be read and re-read individually, from which an initial coding framework will be developed. Team members will meet to discuss the preliminary coding framework and themes to ensure that the emerging analysis is trustworthy and credible. This framework will be added to and refined, with coded material regrouped as new data from subsequent interviews are gathered.

### **Patient and public involvement / Patient Advisory Group (PAG)**

Discussions with women who have perinatal mental health problems and are currently using services, colleagues running voluntary sector perinatal mental health services and feedback from public engagement events, have all highlighted the need to improve psychological treatment services available to women and their partners during pregnancy and following childbirth. We asked women attending an antenatal group for those with mental health problems in pregnancy what they thought would have helped them most and they highlighted the need for a therapy that is more specific to pregnant women. Some reported that current treatment offered (CBT) was 'too clinical' and those providing the treatment made little reference to pregnancy or worries about coping with a young baby. We have two collaborators who run voluntary sector organisations providing help to women with mental health problems during the perinatal period. One has been involved in the development of the ideas surrounding this and the other has been providing advice about women's experience of local psychological treatment services, as well as commenting on the proposal and several aspects of the design. At two public engagement events held in Bristol we discussed services for families and how these could be improved. At one event for fathers whose partners struggled with their mood and anxiety during pregnancy or following child birth they gave a clear message that they felt excluded and even treated with suspicion by services. Fathers welcomed any psychological treatment which might include them and focus on improving the relationship with their partner. Six women who have been attending either an antenatal group aimed at promoting emotional wellbeing or postnatal drop-in sessions run by the voluntary sector, have agreed to form a Patient Advisory Group (PAG) meeting three times during the study.

The PAG members will assist in the development of patient facing materials, advise on recruitment issues, inform the development of the topic guide for the qualitative interviews and discuss and help interpret the results including the decision on whether to proceed to a full trial. They will be offered a study specific induction pack which will include the INVOLVE materials and relevant study information. Training workshops run by People and Research West of England will also be offered to them. PAG members will have their travel expenses and meeting time reimbursed with vouchers. Our findings will be presented in lay terms at a PAG meeting and they will advise us on routes for dissemination to patient groups.

## ETHICS, MONITORING AND DISSEMINATION

This manuscript is based on Protocol V.3.0 dated 14/06/2019. The study received North of Scotland Research Ethics Committee (REC) approval on October 29<sup>th</sup> 2018 and Health Research Authority approval on November 14<sup>th</sup> 2018. The trial will be conducted in accordance with the protocol, the principles of the Declaration of Helsinki and ICH GCP. Any amendments of the protocol will be submitted to the REC for approval. On request, the study investigators and their institutions will permit trial-related monitoring and audits by the Sponsor and relevant Research Ethics Committee by providing direct access to source data and other documents (i.e. patients' hospital notes). The University of Bristol holds the relevant insurance for this study and is the nominated sponsor for this study.

A Trial Steering Committee (TSC) has been convened to provide overall supervision of the trial and ensure it is in accordance with the principles of good clinical practice and relevant regulations. The TSC agreed the trial protocol and will agree any protocol amendments. The TSC also provide advice to the investigators on all aspects of the trial including aspects of safety and monitoring of serious adverse events. The TSC is chaired by Prof Paul Ramchandani with three independent members who have expertise in clinical psychology and perinatal mental health, midwifery for NHS England, and statistics.

### Dissemination.

A lay summary of the study is available on the NIHR website. Results of this feasibility study will be publicly available through open access publication in a peer-reviewed journals and presented at relevant conferences and research meetings. The PPI groups will contribute to the dissemination plan and assist in the production of the lay summaries.

Word count 3979

**Acknowledgements** The authors would like to thank the lay representatives who contribute to the trial management and steering groups and the women who contributed to the intervention design.

**Author Contributions:** JE is the chief investigator and JI drafted the paper with critical input from all authors. All authors contributed to study design and development. JE, JI, HO'M, DK,

1  
2  
3 HT, JR, RL, IC and JF contributed to the inception of the study. DJ, BH, SJ and JG  
4 contributed to revisions of the protocol. DJ, BH are currently recruiting participants to the  
5 trial. All authors read, commented on and approved the final manuscript.  
6  
7

8 **Funding:** This work is supported by the National Institute for Health Research (NIHR)  
9 Research for Patient Benefit research programme grant number PB-PG-1216-20027.  
10  
11

12 **Disclaimer:** The views expressed are those of the authors and not necessarily those of the  
13 NHS, the NIHR or the Department of Health.  
14  
15

16 **Competing interests:** None  
17

18 **Provenance and peer review:** Not commissioned; externally peer reviewed.  
19  
20

21 **Data sharing statement:** The results of this feasibility study will inform the planning of a  
22 definitive randomised controlled trial, including whether it can be conducted, by assessing  
23 rates of recruitment, retention and data collection. Data will be made available upon  
24 reasonable request.  
25  
26  
27

28 **Trial status:** Ongoing data collection.  
29

30 **Trial sponsor:** University of Bristol. Bristol BS1 5DD: [research-governance@bristol.ac.uk](mailto:research-governance@bristol.ac.uk)  
31  
32  
33  
34  
35  
36  
37  
38  
39

## 40 REFERENCES.

41

- 42  
43 1. Howard, L.M., Ryan, E.G., Trevillion, K., Anderson, F., Bick, D., Bye, A. et al. (2018).  
44 Accuracy of the Whooley questions and the Edinburgh Postnatal Depression Scale in  
45 identifying depression and other mental disorders in early pregnancy. *British Journal of*  
46 *Psychiatry*, 212: 50-56.  
47  
48 2. Gavin, N. I., Gaynes, B. N., Lohr, K. N., Meltzer-Brody, S., Gartlehner, G., & Swinson, T.  
49 (2005). Perinatal depression: a systematic review of prevalence and incidence. *Obstetrics &*  
50 *Gynecology*, 106(5, Part 1), 1071-1083.  
51  
52 3. Grigoriadis, S., Vonderporten, E.H., Mamisashvili, L., Tomlinson, G., Dennis, C.L., Koren,  
53 G. et al. (2013). The impact of maternal depression during pregnancy on perinatal  
54 outcomes: A systematic review and meta-analysis. *Journal of Clinical Psychiatry*, 74(4): 321  
55  
56 4. Pedersen, L.H., Henriksen, T.B. and Olsen, J. (2010) Fetal exposure to antidepressants  
57 and normal milestone development at 6 and 19 months of age. *Pediatrics*, 125(3): 600-608  
58  
59  
60

- 1  
2  
3 5. Madigan, S., Oatley, H., Racine, N., Fearon, R.M.P., Schumacher, L., Akbari, E. et al.  
4 (2018). A meta-analysis of maternal prenatal depression and anxiety on child  
5 socioemotional development. *Journal of the American Academy of Child and Adolescent*  
6 *Psychiatry*, 57(9): 645  
7
- 8  
9 6. Cohen, L.S., Altshuler, L.L., Harlow, B.L., Nonacs, R., Newport, D.J., Viguera, A.C. et al.  
10 (2006). Relapse of major depression during pregnancy in women who maintain or  
11 discontinue antidepressant treatment. *Journal of the American Medical Association*, 295(5):  
12 499-507.  
13
- 14 7. NICE Clinical guideline 192 (2014) Antenatal and postnatal mental health: clinical  
15 management and service guidance.  
16
- 17 8. Bosanquet, K., Bailey, D., Gilbody, S., Harden, M., Manea, H., Nutbrown, S. and  
18 McMillan, D. (2015). Diagnostic accuracy of the Whooley questions for the identification of  
19 depression: A diagnostic meta-analysis. *British Medical Journal Open*. 5(12)  
20
- 21 9. Darwin, Z., McGowan, L. and Edozien, L.C. (2015). Antenatal mental health referrals:  
22 Review of local clinical practice and pregnant women's experiences in England. *Midwifery*,  
23 31(3): 17-22  
24
- 25 10. Dennis, C. L., Ross, L. E., & Grigoriadis, S. (2007). Psychosocial and psychological  
26 interventions for treating antenatal depression. *Cochrane Database of Systematic Reviews*  
27 2007, Issue 3. Art. No.: CD006309. DOI: 10.1002/14651858.CD006309.pub2.  
28
- 29 11. Arch, J.J. (2014). Cognitive behavioral therapy and pharmacotherapy for anxiety:  
30 Treatment preferences and credibility among pregnant and non-pregnant women.  
31 *Behaviour Research and Therapy* 52:53-60  
32
- 33 12. Hayes, R.M., Wu, P.S., Shelton, R.C., Cooper, W.O., Dupont, W.D., Mitchel, E. and  
34 Hartert, T.V. (2012) Maternal antidepressant use and adverse outcomes: A cohort study of  
35 228876 pregnancies. *American Journal of Obstetrics and Gynecology*, 207(1)  
36
- 37 13. Bilszta, J.L.C., Tsuchiya, S., Han, K., Buist, A.E., Einarson, A. (2011). Primary care  
38 physicians' attitudes and practices regarding antidepressant use during pregnancy: A survey  
39 of two countries. *Archives of Womens Mental Health*. 14(1): 71-75  
40
- 41 14. Chisolm, M.S. and Payne, J.L. (2016) Management of psychotropic drugs during  
42 pregnancy. *British Medical Journal*, 352:h5918  
43
- 44 15. Sockol, L. E., Epperson, C. N., & Barber, J. P. (2011). A meta-analysis of treatments for  
45 perinatal depression. *Clinical Psychology Review*, 31(5), 839-849.  
46
- 47 16. Beck, A.T. (1967) *Depression: Clinical, Experimental, and Theoretical Aspects*. New  
48 York: Harper & Row.  
49
- 50 17. Johansen, S.L., Robakis, T.K., Williams, K.E. and Rasgon, N.L. (2019) Management of  
51 perinatal depression with non-drug interventions. *British Medical Journal*, 364:l322.  
52
- 53 18. Cox, E.Q., Sowa, N.A., Meltzer-Brody, S.E. and Gaynes, B.N. (2016) The perinatal  
54 depression treatment cascade: Baby steps toward improving outcomes. *Journal of Clinical*  
55 *Psychiatry*, 77(9):1189-1200.  
56  
57  
58  
59  
60

- 1  
2  
3 19. Ravitz, P., Watson, P., Lawson, A., Contatino, M.J., Bernecker, S., Park, J. and Swartz,  
4 H.A. (2019) Interpersonal psychotherapy: A scoping review and historical perspective  
5 (1974-2017). *Harvard Review of Psychiatry*. Accessed online via PMID 30883446.  
6  
7 20. Lipsitz, J. D., & Markowitz, J. C. (2013). Mechanisms of change in interpersonal therapy  
8 (IPT). *Clinical psychology review*, 33(8), 1134-1147.  
9  
10 21. Lancaster, C. A., Gold, K. J., Flynn, H. A., Yoo, H., Marcus, S. M., & Davis, M. M. (2010).  
11 Risk factors for depressive symptoms during pregnancy: a systematic review. *American*  
12 *Journal of Obstetrics and Gynecology*, 202(1), 5-14.  
13  
14 22. NHS Digital 2016: Psychological Therapies: Annual Report on the use of IAPT services,  
15 England, 2015-16  
16  
17 23. Menchetti, M., Rucci, P., Bortolotti, B., Bombi, A., Scocco, P., Kraemer, H. C., Berardi D,  
18 DEPICS group. (2013). Moderators of remission with interpersonal counselling or drug  
19 treatment in primary care patients with depression: randomised controlled trial. *The British*  
20 *Journal of Psychiatry*. 204(2): 144-150.  
21  
22 24. Wilkinson PO, Cestaro V, Pinchen I. Pilot mixed-methods evaluation of interpersonal  
23 counselling for young people with depressive symptoms in non-specialist services  
24 *Evidence-Based Mental Health* 2018;**21**:134-138.  
25  
26 25. Lenze, Shannon N., and Mary Anne Potts. (2017) Brief Interpersonal Psychotherapy for  
27 depression during pregnancy in a low-income population: A randomized controlled trial  
28 *Journal of Affective Disorders* 210: 151-157.  
29  
30 26. Stuart, S. (2012). Interpersonal psychotherapy for postpartum depression. *Clinical*  
31 *Psychology & Psychotherapy*, 19(2), 134-140.  
32  
33 27. Bauer, A., Parsonage, M., Knapp, M., Lemmi, V., & Adelaja, B. (2014). Costs of perinatal  
34 mental health problems. London School of Economics and Political Science.  
35  
36 28. Lewis G, Pelosi AJ, Araya R, Dunn G: (1992) Measuring psychiatric-disorder in the  
37 community – a standardized assessment for Use by Lay interviewers. *Psychol Med*. 22 (2):  
38 465-486.  
39  
40 29. Burns, A., O'Mahen, H., Baxter, H., Bennert, K., Wiles, N., Ramchandani, P., ... & Evans,  
41 J. (2013). A pilot randomised controlled trial of cognitive behavioural therapy for antenatal  
42 depression. *BMC Psychiatry*, 13(1), 33.  
43  
44 30. Wilkinson, E. L., O'Mahen, H. A., Fearon, P., Halligan, S., King, D. X., Greenfield, G., ...  
45 & Ramchandani, P. G. (2016). Adapting and testing a brief intervention to reduce maternal  
46 anxiety during pregnancy (ACORN): study protocol for a randomised controlled trial. *Trials*,  
47 17(1), 156.  
48  
49 31. Redshaw, M., & Henderson, J. (2013). Fathers' engagement in pregnancy and childbirth:  
50 evidence from a national survey. *BMC Pregnancy and Childbirth*, 13(1), 70.  
51  
52 32. Cox, J. L., Holden, J. M., & Sagovsky, R. (1987). Detection of postnatal depression.  
53 Development of the 10-item Edinburgh Postnatal Depression Scale. *The British Journal of*  
54 *Psychiatry*, 150(6), 782-786.  
55  
56 33. Hewitt C, Gilbody S, Brealey S, et al. (2009) Methods to identify postnatal depression in  
57 primary care: an integrated evidence synthesis and value of information analysis. *Health*  
58  
59  
60

1  
2  
3 Technol Assess.13(36):1-145, 147-230.  
4

5 34. Edmondson OJ, Psychogiou L, Vlachos H, Netsi E, Ramchandani PG. (2010)  
6 Depression in fathers in the postnatal period: assessment of the Edinburgh Postnatal  
7 Depression Scale as a screening measure. *J Affect Disord.*125(1-3):365-368.  
8

9 35. Busby DM, Christensen C, Crane DR, Larson JH. (1995). A revision of the dyadic  
10 adjustment scale for use with distressed and nondistressed couples: construct hierarchy and  
11 multidimensional scales. *Journal of Marital and Family Therapy*; 21(3):289-308.  
12

13 36. Condon JT. (1993) The assessment of antenatal emotional attachment: development of  
14 a questionnaire instrument. *Br J Med Psychol*; 66 (Pt 2): 167-183  
15

16 37. Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonnel, G., Badia,  
17 X. (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-  
18 5D-5L) *Quality of Life Research*, 20(10), pp1727-1736.  
19

20 38. Braun, V., & Clarke, V. (2006), Using thematic analysis in psychology. *Qualitative*  
21 *Research in Psychology*, 3, 77-101.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 Figure 1. ADAGIO study flow diagram  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60






Figure 1 ADAGIO study flow diagram

90x89mm (300 x 300 DPI)



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

## SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	__ 1 __
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	__ 2 __
	2b	All items from the World Health Organization Trial Registration Data Set	__ N/A __
Protocol version	3	Date and version identifier	__ 15 __
Funding	4	Sources and types of financial, material, and other support	__ 16 __
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	__ 15 __
	5b	Name and contact information for the trial sponsor	__ 16 __
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	__ 15/16 __
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	__ 15 __

## 1 Introduction

2			
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant
4	rationale		studies (published and unpublished) examining benefits and harms for each intervention
5			
6		6b	Explanation for choice of comparators
7			
8	Objectives	7	Specific objectives or hypotheses
9			
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),
11			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
12			
13			

## 14 Methods: Participants, interventions, and outcomes

15			
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will
17			be collected. Reference to where list of study sites can be obtained
18			
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and
20			individuals who will perform the interventions (eg, surgeons, psychotherapists)
21			
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be
23			administered
24		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose
25			change in response to harms, participant request, or improving/worsening disease)
26		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence
27			(eg, drug tablet return, laboratory tests)
28		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
29			
30			
31			
32	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood
33			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,
34			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen
35			efficacy and harm outcomes is strongly recommended
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			

1	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	_8-11_____
2				
3				
4	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	_11_____
5				
6				
7	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	_8_____
8				
9				
10	<b>Methods: Assignment of interventions (for controlled trials)</b>			
11	Allocation:			
12				
13	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	_9_____
14				
15				
16				
17				
18				
19	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	_9_____
20				
21				
22				
23				
24	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	_8-9_____
25				
26				
27	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	_10__
28				
29				
30		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	_na_____
31				
32				
33				
34	<b>Methods: Data collection, management, and analysis</b>			
35				
36	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	_10-11__
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

1		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	__10__
2				
3				
4	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	__9__
5				
6				
7				
8	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	__13__
9				
10				
11		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	__na__
12				
13		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	__na__
14				
15				
16				
17	<b>Methods: Monitoring</b>			
18				
19	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	__15__
20				
21				
22				
23				
24		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	__na__
25				
26				
27				
28	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	__15__
29				
30				
31	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	__15__
32				
33				
34				
35	<b>Ethics and dissemination</b>			
36				
37	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	__15__
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Protocol	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	__15__
2	amendments			
3				
4				
5	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	8-9__
6				
7				
8		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	__na__
9				
10				
11	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	__9__
12				
13				
14	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	__16__
15				
16				
17				
18	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	__15__
19				
20				
21	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	__na__
22				
23				
24	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, health care professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	__15__
25				
26				
27				
28		31b	Authorship eligibility guidelines and any intended use of professional writers	__na__
29				
30		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	__16__
31				
32				
33	<b>Appendices</b>			
34				
35	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	__attached__
36				
37				
38	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	__na__
39				
40				
41				
42				
43				
44				
45				
46				

1 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
2 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
3 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

For peer review only

bmjopen-2019-032649 on 18 August 2019. Downloaded from <http://bmjopen.bmj.com/> on April 27, 2024 by guest. Protected by copyright.